GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT03275103
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Princess Margaret Cancer Center, Toronto, Ontario, Canada
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03237741
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03174041
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03162250
- Locations
- 🇰🇷
Asan Medical Center - Oncology, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
- Conditions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT03154437
- Locations
- 🇺🇸
Tulane Medical Center; Investigational/Research Pharmacy, New Orleans, Louisiana, United States
🇺🇸Children's Mercy Hosp Clinics, Kansas City, Missouri, United States
🇺🇸University of Texas Medical School, Houston, Texas, United States
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT03137069
- Locations
- 🇨🇦
Gordon Sussman Clinical Research, Toronto, Ontario, Canada
🇺🇸New Horizon Research Center, Miami, Florida, United States
🇩🇪Universitätsmedizin Johannes Gutenberg Universität, Mainz, Germany
A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03060538
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸MidWest Clinical Research, Overland Park, Kansas, United States
🇺🇸Premier Research Associate, Inc, Miami, Florida, United States
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03029832
- Locations
- 🇺🇸
Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States
🇺🇸Nebraska Methodist Hospital; Cancer Center, Omaha, Nebraska, United States
🇺🇸University of Colorado, Denver, Colorado, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT02996019
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States